We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
(+41%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
38.29%
Top 10 Holdings %
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$13.6M |
| 2 |
Merck
MRK
|
+$12.5M |
| 3 |
Intuitive Surgical
ISRG
|
+$11.1M |
| 4 |
DOCU
DocuSign
DOCU
|
+$10.9M |
| 5 |
Insulet
PODD
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nasdaq
NDAQ
|
+$7.26M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$6.86M |
| 3 |
Incyte
INCY
|
+$6.31M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.73M |
| 5 |
AbbVie
ABBV
|
+$4.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.41% |
| 2 | Consumer Discretionary | 17.68% |
| 3 | Healthcare | 16.13% |
| 4 | Industrials | 12.13% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Newell Brands
NWL
$2.61B
| $541K | 0.06% |
+59,932
| New | +$596K |
|
377
C.H. Robinson
CHRW
$18.1B
| $537K | 0.06% |
6,240
+3,939
| +171% | +$368K |
|
378
Kenvue
KVUE
$37.5B
| $535K | 0.06% |
+26,644
| New | +$617K |
|
379
Cummins
CMI
$87.8B
| $534K | 0.06% |
+2,339
| New | +$565K |
|
380
Magna International
MGA
$18.7B
| $532K | 0.06% |
+9,926
| New | +$578K |
|
381
XPeng
XPEV
$11.5B
| $531K | 0.06% |
28,917
-65,050
| -69% | -$1.1M |
|
382
National Vision
EYE
$1.85B
| $529K | 0.06% |
32,718
+21,021
| +180% | +$421K |
|
383
Fair Isaac
FICO
$22.6B
| $521K | 0.06% |
+600
| New | +$515K |
|
384
Unum
UNM
$14.5B
| $519K | 0.06% |
+10,546
| New | +$516K |
|
385
FMC
FMC
$1.32B
| $509K | 0.06% |
7,603
-7,502
| -50% | -$650K |
|
386
Magnolia Oil & Gas
MGY
$5.82B
| $506K | 0.06% |
22,092
-34,061
| -61% | -$761K |
|
387
Huntsman Corp
HUN
$1.83B
| $505K | 0.06% |
+20,700
| New | +$561K |
|
|
AEL
388
DELISTED
American Equity Investment Life Holding Company
AEL
| $504K | 0.06% |
9,395
-26,341
| -74% | -$1.41M |
|
|
TPH
389
DELISTED
Tri Pointe Homes
TPH
| $504K | 0.06% |
+18,417
| New | +$565K |
|
390
Colgate-Palmolive
CL
$73.8B
| $503K | 0.06% |
7,076
-15,980
| -69% | -$1.19M |
|
391
Honda
HMC
$39.1B
| $500K | 0.06% |
14,863
+6,179
| +71% | +$199K |
|
392
Dell
DELL
$302B
| $497K | 0.06% |
7,215
-27,077
| -79% | -$1.61M |
|
393
West Pharmaceutical
WST
$24.5B
| $497K | 0.06% |
+1,324
| New | +$512K |
|
394
Occidental Petroleum
OXY
$54.8B
| $491K | 0.06% |
7,563
-69,582
| -90% | -$4.38M |
|
395
Green Brick Partners
GRBK
$3.1B
| $488K | 0.06% |
+11,755
| New | +$588K |
|
396
Aflac
AFL
$63.7B
| $485K | 0.06% |
6,317
-2,793
| -31% | -$207K |
|
397
KLA
KLAC
$255B
| $484K | 0.06% |
+10,550
| New | +$506K |
|
398
Coherent
COHR
$63.3B
| $480K | 0.06% |
14,691
-3,208
| -18% | -$132K |
|
399
Exelixis
EXEL
$14.1B
| $476K | 0.06% |
21,765
+8,305
| +62% | +$174K |
|
400
Elevance Health
ELV
$82B
| $470K | 0.06% |
1,079
+511
| +90% | +$232K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.
- Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
- Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
- Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
- Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
- Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
- Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
- Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.
Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.